Table 3.
Baseline characteristics of hypothetical individuals with T2D
| Patient A | Patient B | Patient C | |
|---|---|---|---|
| Age, years | 60 | 70 | 75 |
| Sex | Male | Female | Male |
| Diabetes duration, years | 10 | 12 | 18 |
| Current smoker | No | Yes | No |
| BMI, kg/m2 | 33 | 28 | 30 |
| HbA1c, mmol/mol | 52 | 48 | 56 |
| SBP, mmHg | 137 | 125 | 140 |
| Non-HDL cholesterol, mmol/L | 3 | 2.5 | 3.5 |
| eGFR, mL/min/1.73 m2* | 75 | 70 | 82 |
| Microalbumin | No | Yes | No |
| Macroalbumin | No | No | No |
| History of CVD | Yes | No | Yes |
| Use of insulin | No | No | Yes |
| 10-year CVD risk, % | 25.4 | 2.9 | 53.2 |
| 10-year CVD risk with the addition of semaglutide to SoC, % | 19.9 | 2.2 | 44.2 |
eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
Estimated using the CKD-EPI creatinine equation.